Showing results (61-70 of 108) with videos related to
Sort By:
Pageof 11
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 21, 2025
Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision-Making PointsEkta Seth Chhabra, Ali Sadeghi-Khomami, Mingjie Liu, et al.Journal of Thrombosis and Haemostasis : JTH|January 19, 2024
Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene TherapyWolfgang Miesbach, Barbara Konkle, Pratima Chowdary, et al.Gastroenterology|February 8, 2018
HIF1-alpha Regulates Acinar Cell Function and Response to Injury in Mouse PancreasMin-Jung Park, Sapna Iyer, Xiang Xue, et al.Therapeutic Advances in Hematology|December 23, 2024
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trialDoris V Quon, Jiaan-Der Wang, Michael Wang, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|June 19, 2025
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by InhibitorsTyler W Buckner, Craig Kessler, Giancarlo Castaman, et al.Blood Advances|November 8, 2019
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia BAnnette Von Drygalski, Adam Giermasz, Giancarlo Castaman, et al.Research and Practice in Thrombosis and Haemostasis|April 1, 2024
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studiesJohnny Mahlangu, Víctor Jiménez-Yuste, Giuliana Ventriglia, et al.Journal of Thrombosis and Haemostasis : JTH|December 17, 2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting databaseSteven W Pipe, Rebecca Kruse-Jarres, Johnny N Mahlangu, et al.Research and Practice in Thrombosis and Haemostasis|January 29, 2024
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeksAnna Kiialainen, Joanne I Adamkewicz, Claire Petry, et al.The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.Pageof 11